Evolus raised the lower end of its 2026 revenue guidance to $330 million while maintaining the upper end at $337 million, and reaffirmed a long-term target of $450 million to $500 million in annual revenue with a 13% to 15% adjusted EBITDA margin in 2028. The company reported second-quarter global net revenue of $84.1 million, beating analysts' estimates, and posted positive adjusted EBITDA of $4.7 million, marking its third consecutive quarter of profitability on that basis. Management highlighted the successful European launch of the Estyme collection and a new licensing agreement with IBSA for exclusive U.S. rights to Profhilo, a product it believes can generate more than $100 million in peak annual revenue, though U.S. approval is not anticipated until around 2030. Evolus also raised its full-year adjusted gross profit margin guidance to between 67.0% and 67.5%, and narrowed its non-GAAP operating expense range to $212 million to $216 million. The company ended the quarter with $45.2 million in cash and access to an additional $100 million in liquidity, and said it does not anticipate needing additional equity financing.
Evolus IncRaises 2026 revenue outlook, beats Q2 estimates, and posts positive adjusted EBITDA.
Licensing agreement with Evolus for U.S. rights to Profhilo, expected to generate over $100 million in peak revenue.
